In addition, the discovery of the function of EFEMP1 as a tumor suppressor that modulates EGFR suggests a need to further investigate EFEMP1 as a potential predictive marker for anti-EGFR therapies of cancer, including glioblastoma, lung, breast, prostate, and liver cancers. This evidence concerns the gene EGFR and liver cancer.